Bachem Holding AG, a technology-based biochemicals company, provides services to the pharmaceutical and biotechnology industries primarily in Europe and North America. It develops and manufactures peptide active pharmaceutical ingredients (APIs), as well as biochemicals for research purposes. The company offers research products, which include catalog products comprising peptides, amino acid derivatives, and biochemicals for peptide research; custom synthesis services; sterile products under the Clinalfa brand; and glycosylated peptides to enhance drugs. It also provides API products comprising generic APIs used in the fields of cancer, diabetes, obesity, fertility, and others; and new chemical entities. In addition, the company offers customer support services, such as formulation development, sterile tox-vials, compatibility studies, stress tests, post-release stability studies, and other services. Bachem Holding AG was founded in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.
bachem holding ag-reg b
(BANB:SIX Swiss Ex)
Phone: 41 58 595 2021
Fax: 41 58 595 2041www.bachem.com
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for BANB.|
|View Industry Companies|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact BACHEM HOLDING AG-REG B, please visit www.bachem.com. Company data is provided by Capital IQ. Please use this form to report any data issues.